MPDZ

Across TCGA pan-cancer cohorts, MPDZ mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MPDZ data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MPDZ mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MPDZ expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where MPDZ mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	III,IV	0.842	0.520	.003	24	view →
CCRCC	OS	Median	All	1.000	0.888	.003	9	view →
LSCC	DFS	Median	All	0.610	0.793	.017	7	view →
LUAD	DFS	Tertile	III,IV	0.346	0.899	.012	7	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MPDZ–HNSC (OS)

Open the HNSC breakdown →